Moderna: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 994106923 by Osterluzei (talk) Sorry, this is just a republished version of the press release …
Used independent source (Ireland), re-worded sentence, and introduced quotes. This is a factual and objective entry.
Line 105: Line 105:


On November 2020, ''[[Nature (journal)|Nature]]'' reported that "While it's possible that differences in LNP formulations or mRNA secondary structures could account for the thermostability differences [between Moderna and BioNtech], many experts suspect both vaccine products will ultimately prove to have similar storage requirements and shelf lives under various temperature conditions".<ref name=nature1>{{cite journal | journal=[[Nature (journal)|Nature]] | date=25 November 2020 | accessdate=30 November 2020 | first=Ellie | last=Dogan | title=COVID-19 vaccines poised for launch, but impact on pandemic unclear | url=https://www.nature.com/articles/d41587-020-00022-y | doi=10.1038/d41587-020-00022-y| pmid=33239758 | s2cid=227176634 }}</ref>
On November 2020, ''[[Nature (journal)|Nature]]'' reported that "While it's possible that differences in LNP formulations or mRNA secondary structures could account for the thermostability differences [between Moderna and BioNtech], many experts suspect both vaccine products will ultimately prove to have similar storage requirements and shelf lives under various temperature conditions".<ref name=nature1>{{cite journal | journal=[[Nature (journal)|Nature]] | date=25 November 2020 | accessdate=30 November 2020 | first=Ellie | last=Dogan | title=COVID-19 vaccines poised for launch, but impact on pandemic unclear | url=https://www.nature.com/articles/d41587-020-00022-y | doi=10.1038/d41587-020-00022-y| pmid=33239758 | s2cid=227176634 }}</ref>

Since September 2020, Moderna has used [[Roche Diagnostics]]' Elecsys® Anti-SARS-CoV-2 S test, approved by the US FDA on November 25, 2020. According to an independent supplier of clinical assays in microbiology, "this will facilitate the quantitative measurement of SARS-CoV-2 antibodies and help to establish a correlation between vaccine-induced protection and levels of anti-receptor binding domain (RBD) antibodies". The partnership was announced by Roche on December 9, 2020.<ref>[https://www.rapidmicrobiology.com/news/moderna-use-roche-antibody-test-during-vaccine-trials "Moderna Use Roche Antibody Test During Vaccine Trials"]. ''rapidmicrobiology.com''. Retrieved 13 December, 2020.</ref>


===Purchase commitments===
===Purchase commitments===

Revision as of 04:14, 14 December 2020

Moderna, Inc.
FormerlyModeRNA Therapeutics
(2010–2018)
Company typePublic
IndustryBiotechnology
FoundedSeptember 2010; 13 years ago (2010-09)
Founders
Headquarters200 Technology Square
Cambridge, Massachusetts, U.S.[3]
Key people
Productsnone
RevenueDecrease US$60.20 million (2019)[6]
Decrease US$−546 million (2019)[6]
Decrease US$−514 million (2019)[6]
Total assetsIncrease US$1.589 billion (2019)[6]
Total equityDecrease US$1.174 billion (2019)[6]
Number of employees
830 (2019)[6]
Websitemodernatx.com

Moderna is an American biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA).[7][8]

Moderna's technology platform inserts synthetic nucleoside-modified mRNA (modRNA) into human cells. This mRNA then reprograms the cells to prompt immune responses. It is a novel technique, previously abandoned due to the side effects of inserting mRNA into cells.[9][10][11] As of November 2020, the Moderna COVID-19 vaccine candidate, mRNA-1273, had shown preliminary evidence of 94% efficacy in preventing COVID-19 disease in a Phase III trial, with only minor flu-like side effects. This led to its submission for emergency use authorization in Europe, the United States, and Canada.[12][13]

History

2010–2016

In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi. Rossi had developed a method of modifying mRNA by first transfecting it into human cells, then dedifferentiating it into stem cells which could then be further redifferentiated into desired target cell types.[14][15] Rossi approached fellow Harvard University faculty member Tim Springer, who solicited co-investment from Kenneth Chien, Bob Langer, and venture capital firm Flagship Ventures.[15][16]

In 2011, the CEO of Flagship Ventures (now Flagship Pioneering), Noubar Afeyan, brought in European pharma sales and operations executive Stéphane Bancel as CEO.[15][9] Afeyan personally owned 19.5% of Moderna and was the largest single shareholder, while his fund, Flagship Pioneering, owned 18%.[17]

In March 2013, Moderna and AstraZeneca signed a five-year exclusive option agreement to discover, develop, and commercialize mRNA for treatments in the therapeutic areas of cardiovascular, metabolic, and renal diseases, and selected targets for cancer.[9][18][19] The agreement included a $240 million upfront payment to Moderna, a payment that was "one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials",[18] and an 8% share in Moderna.[17] As of May 2020, only one candidate has passed Phase I trials, a treatment for myocardial ischemia, labelled AZD8601.[a][21]

In January 2014, Moderna and Alexion Pharmaceuticals entered a $125 million deal for orphan diseases in need of therapies. Alexion paid Moderna $100 million for 10 product options to develop rare-disease treatments, including for Crigler-Najjar syndrome, using Moderna's mRNA therapeutics platform.[22] By 2016, Bancel told an audience of JPMorgan Chase investors that the work with Alexion would shortly enter human trials. However, by 2017, the program with Alexion had been scrapped as the animal trials showed that Moderna's treatment would never be safe enough for use in humans.[9][11]

Most of the biotech community did not value vaccines. It was very hard to move that stuff forward. Because people said, "Oh, vaccines, nobody's going to pay for that."

Jeff Ellsworth, Former Senior Director of Preclinical Pharmacology and Head of Rare Genetic Diseases, Moderna (2020)[8]

In 2014, after disappointing standalone therapeutic trials,[b] Moderna moved to focus on mRNA vaccines given that, efficacy issues aside, mRNA will always stimulate a level of antibody development in subjects.[8][11] The change in strategy had risk given the materially lower margins of vaccine development (called "loss-leaders" by some Moderna employees),[8] with some senior employees and industry experts questioning the future viability of the company.[8][11] Rossi left the company.[8]

In February 2016, an op-ed in Nature criticized Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos.[24] In September 2018, Thrillist published article titled, "Why This Secretive Tech Start-Up Could Be The Next Theranos",[25] criticizing its reputation for secrecy and the absence of scientific validation or independent peer-review of its research, though having the highest valuation of any U.S. private biotech company at more than $5 billion.[9][10] A former Moderna scientist told Stat: "It's a case of the emperor's new clothes. They're running an investment firm, and then hopefully it also develops a drug that's successful".[9]

2018–2020

In 2018, the company rebranded as "Moderna Inc." with the ticker symbol MRNA, and further increased its portfolio of vaccine development.[8] In December 2018, Moderna became the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share) on NASDAQ, and implying an overall valuation of $7.5 billion for the entire company.[26][27] The year-end 2019 SEC filings showed that Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019 alone, and had raised $3.2 billion in equity since 2010.[8][17] As of December 2020, Moderna was valued at $60 billion.[28]

In March 2020, in a White House meeting between the Trump administration and pharmaceutical executives, Bancel told the president that Moderna could have a COVID-19 vaccine ready in a few months.[8] The next day, the FDA approved clinical trials for the Moderna vaccine candidate, with Moderna later receiving investment of $483 million from Operation Warp Speed.[8] Moderna board member, Moncef Slaoui, was appointed head scientist for the Operation Warp Speed project.[8]

Overview

Moderna develops mRNAs that are delivered in lipid nanoparticle, using mRNA with pseudouridine nucleosides. Candidates are designed to have improved folding and translation efficiency via insertional mutagenesis. [29] As of August 2020, no RNA (or RNA vaccine) had been licensed for prophylactic use in humans.[30]

The Moderna COVID-19 vaccine candidate, mRNA-1273, was shown in a Phase I trial to be immunogenic in a small number of volunteers aged 18-55 years.[31]

Leadership

Since 2011, Moderna has been led by CEO Stéphane Bancel, a French businessman with a pharmaceutical sales and operations background.[9][8] Bancel has been described as having a secretive approach to Moderna, and as being a tough operator.[9][8] Though never having worked with RNA before, Stat noted that Bancel "is listed as a co-inventor on more than 100 of Moderna's early patent applications, unusual for a CEO who is not a PhD scientist".[9] After Noubar Afeyan and Robert Langer, Bancel is the largest individual shareholder in the company.[32]

Stephen Hoge, M.D., is President and a former McKinsey & Company management consultant who joined in 2012; he is the fourth-largest individual shareholder in the company.[32][5]

David Meline is CFO.[5]

Stock sales

On 18 May 2020, when Moderna announced it was making progress with its coronavirus vaccine, company stock rose 30%. That day, CFO Lorence Kim bought stock for $3 million and immediately sold it for $19.8 million. The next day, chief medical officer Tal Zaks bought stock for $1.5 million and immediately sold it for $9.77 million. Both of these executives were using automated insider trading plans known as 10b5-1 plans.[33]

On 21 and 22 May, Moderna's leading shareholder, the venture capital firm Flagship Pioneering, made $69.5 million by selling Moderna stock. Flagship is listed as a Moderna "insider" but did not use an automated 10b5-1 plan for these sales.[34]

Board

Noubar Afeyan, CEO of Flagship Pioneering, has been the chairman of Moderna's board of directors since 2011.[35] Afeyan who has a Ph.D. in biochemical engineering[36] holds his interest in Moderna through various Flagship Pioneering vehicles. At the 2018 IPO, documents filed stated that Afeyan owned 19.5% of the company, while Flagship owned 18%, thus giving Afeyan control over 37.5% of the company.[17]

In May 2020, board member Dr. Moncef Slaoui resigned from the company to become Chief Scientist for the Trump administration's "Operation Warp Speed", a group designed to accelerate the development of a vaccine for the coronavirus. Slaoui continued to hold more than $10 million in stock options in the company in his new role while the federal government invested $483 million in the company to assist in coronavirus vaccine trials. Senator Elizabeth Warren called the holding a conflict of interest and stated that Slaoui should have divested his options.[37]

COVID-19 vaccine candidate

See also: COVID-19 vaccine § Clinical trials started in 2020, and RNA vaccine

Design and Phase I-II trials

In January 2020, Moderna announced development of an RNA vaccine, named mRNA-1273, to induce immunity to SARS-CoV-2.[38][39][40] Moderna's technology is a nucleoside-modified messenger RNA (modRNA) compound named mRNA-1273, which induces immunity to SARS-CoV-2 by encoding a prefusion stabilized spike (S) protein naturally present on the surface of SARS-CoV-2 particles. From the announcement, Moderna's shares rose dramatically, and the CEO and other corporate executives began large program sales of their shareholdings.[41]

In March 2020, the Phase I human trial of mRNA-1273 began in partnership with the US National Institute of Allergy and Infectious Diseases.[42] In April, the U.S. Biomedical Advanced Research and Development Authority (BARDA) allocated up to $483 million for Moderna's vaccine development.[43] Plans for a Phase II dosing and efficacy trial to begin in May were approved by the FDA.[44] Moderna signed a partnership with Swiss vaccine manufacturer Lonza Group,[45] to supply 300 million doses per annum.[46]

On May 25 2020, Moderna began a Phase IIa clinical trial recruiting 600 adult participants to assess safety and differences in antibody response to two doses of its candidate vaccine, mRNA-1273, a study expected to complete in 2021.[47] In June 2020, Moderna entered a partnership with Catalent in which Catalent will fill and package the vaccine candidate. Catalent will also provide storage and distribution.[48]

On July 9, Moderna announced an in-fill manufacturing deal with Laboratorios Farmacéuticos Rovi, in the event that its vaccine is approved.[49]

On 14 July 2020, Moderna scientists published preliminary results of the Phase I dose escalation clinical trial of mRNA-1273, showing dose-dependent induction of neutralizing antibodies against S1/S2 as early as 15 days post-injection. Mild to moderate adverse reactions, such as fever, fatigue, headache, muscle ache, and pain at the injection site were observed in all dose groups, but were common with increased dosage. [50][51] The vaccine in low doses was deemed safe and effective in order to advance a Phase III clinical trial using two 100-μg doses administered 29 days apart.[50]

In July 2020, Moderna announced in a preliminary report that its Operation Warp Speed candidate had led to production of neutralizing antibodies in healthy adults in Phase I clinical testing.[50][52] "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection."[53] The troublesome higher doses were discarded in July from future studies.[53]

Criticisms

In May 2020, after releasing partial and non-peer reviewed results for only 8 of 45 candidates in a preliminary pre-Phase I stage human trial direct to stock markets, the CEO announced on CNBC an immediate $1.25 billion rights issue to raise funds for the company, at a $30 billion valuation.[54] while Stat said, "Vaccine experts say Moderna didn't produce data critical to assessing COVID-19 vaccine".[55]

On July 7, disputes between Moderna and government scientists over the company's unwillingness to share data from the clinical trials were revealed.[56]

Phase III trials

Moderna and the National Institute of Allergy and Infectious Diseases began a Phase III trial in the United States on 27 July with a plan to enroll and assign 30,000 volunteers to two groups — one group receiving two 100-μg doses of mRNA-1273 vaccine and the other receiving a placebo of 0.9% sodium chloride.[57] As of 7 August, over 4,500 volunteers had enrolled.

On September 2020, Moderna published the detailed study plan for the clinical trial.[58] On 30 September, CEO Stéphane Bancel said that, if the trial is successful, the vaccine might be available to the public as early as late March or early April 2021.[59] As of October 2020, Moderna had completed the enrollment of 30,000 participants needed for its Phase III trial.[60]

On 16 November 2020, Moderna announced preliminary data from its Phase III clinical trial, indicating 94% efficacy in preventing COVID-19 infection.[61][62] Side effects included flu-like symptoms, such as pain at the injection site, fatigue, muscle pain, and headache.[61] The Moderna results were not final – as the trial is not scheduled to conclude until late-2022[63] – and were not peer-reviewed or published in a medical journal.[61] The US National Institutes of Health announced on 15 November 2020 that overall trial results were positive.[64]

It remains unknown whether the Moderna vaccine candidate is safe or effective in people under age 18, how long it provides immunity, whether it requires a booster shot,[61] or whether it is effective in people of color.[65] The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to 30 days or −20 °C (−4 °F) for up to 4 months, whereas the Pfizer candidate requires ultracold freezer storage at −70 °C (−94 °F).[61]

On November 2020, Nature reported that "While it's possible that differences in LNP formulations or mRNA secondary structures could account for the thermostability differences [between Moderna and BioNtech], many experts suspect both vaccine products will ultimately prove to have similar storage requirements and shelf lives under various temperature conditions".[66]

Since September 2020, Moderna has used Roche Diagnostics' Elecsys® Anti-SARS-CoV-2 S test, approved by the US FDA on November 25, 2020. According to an independent supplier of clinical assays in microbiology, "this will facilitate the quantitative measurement of SARS-CoV-2 antibodies and help to establish a correlation between vaccine-induced protection and levels of anti-receptor binding domain (RBD) antibodies". The partnership was announced by Roche on December 9, 2020.[67]

Purchase commitments

On 11 August 2020, the US government signed an agreement to buy 100 million doses of Moderna's anticipated vaccine,[68] which the Financial Times said Moderna planned to price its vaccine between $50–60 per course.[69] On November 2020, Moderna has stated that it will charge governments who purchase its vaccine between $25 and $37 per dose while the EU is seeking a price of under $25 per dose for the 160 million doses it plans to purchase from Moderna.[70][71]

In late 2020, Moderna also obtained purchase agreements for mRNA-1273 with the European Union for 160 million doses and with Canada for up to 56 million doses.[72][73]

Emergency use authorization

During October-December 2020, mRNA-1273 was under evaluation for emergency use authorization (EUA) which would enable rapid rollout of the vaccine in the United Kingdom, other countries of Europe, Canada, and the United States.[8][12][13][74]

Patent litigation

The PEGylated lipid nanoparticle (LNP) drug delivery system of mRNA-1273 has been the subject of ongoing patent litigation with Arbutus Biopharma, from whom Moderna had previously licensed LNP technology.[75][76] On September 2020, Nature Biotechnology reported that Moderna had lost a key challenge in the ongoing case.[77]

See also

Notes

  1. ^ The relative success of AZD8601 is attributed to the fact that Moderna has been able to inject mRNA direct into the heart muscle without needing a drug delivery system. However, only the heart and some skin areas are capable of absorbing "naked mRNA".[20]
  2. ^ Competitor mRNA biotech CureVac had a more spectacular experience in 2017 with the Phase II failure of its prostate cancer therapy, CV9104, which led CEO Ingmar Hoerr to say that "CureVac no longer sees mRNA as a stand-alone therapy", and "What we've learned here is that mRNA is not enough on its own ..".[23]

References

  1. ^ "What we know about Moderna's COVID-19 vaccine candidate — and what we don't". PBS News Hour. November 16, 2020. Archived from the original on December 4, 2020. Noubar Afeyan is a co-founder and chairman of Moderna...
  2. ^ "Moderna chairman: We don't need deep-freeze conditions for vaccine". CNN. November 16, 2020. Archived from the original on December 4, 2020.
  3. ^ "Key Facts". Moderna. Retrieved May 19, 2020.
  4. ^ Alspach, Kyle (May 22, 2013). "Moderna CEO Bancel joins Flagship Ventures as senior partner". Boston Business Journal (Blog). American City Business Journals. Archived from the original on January 31, 2014. Retrieved March 12, 2020.
  5. ^ a b c "Executive Committee & Leadership". Archived from the original on November 16, 2020. Retrieved August 13, 2020.
  6. ^ a b c d e f "Financial Review - Moderna and Subsidiary Companies". Moderna. 2019. Retrieved March 17, 2020.
  7. ^ Catherine Shaffer (December 6, 2013). "Moderna Makes Entrance with $40M Round for mRNA Work". BioWorld. Archived from the original on November 16, 2020. Retrieved December 11, 2013.
  8. ^ a b c d e f g h i j k l m n Elizabeth Cohen (November 30, 2020). "Moderna applies for FDA authorization for its Covid-19 vaccine". CNN. Retrieved December 4, 2020.
  9. ^ a b c d e f g h i Garade, Damien (September 13, 2016). "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups". Stat. Archived from the original on November 16, 2020. Retrieved May 18, 2020.
  10. ^ a b Crow, David (September 6, 2017). "Secretive Moderna yet to convince on $5bn valuation". Financial Times. Archived from the original on February 3, 2019. Retrieved May 18, 2020.
  11. ^ a b c d Garde, Damien (January 10, 2017). "Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine". Stat. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  12. ^ a b Ludwig Burger (December 1, 2020). "COVID-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approval". Reuters. Retrieved December 4, 2020.
  13. ^ a b Hannah Kuchler (November 30, 2020). "Canada could be among the first to clear Moderna's COVID-19 vaccine for use". The Financial Post. Retrieved December 4, 2020.
  14. ^ Erin Kutz (October 4, 2010). "ModeRNA, Stealth Startup Backed By Flagship, Unveils New Way to Make Stem Cells". Xconomy. Archived from the original on February 8, 2017. Retrieved February 7, 2017.
  15. ^ a b c Gregory Huang (December 6, 2012). "Moderna, $40M in Tow, Hopes to Reinvent Biotech with "Make Your Own Drug"". Xconomy. Archived from the original on November 22, 2018. Retrieved June 21, 2013.
  16. ^ Catherine Elton (March 2013). "The NEXT Next Big Thing". Boston Magazine. Archived from the original on November 16, 2020. Retrieved December 11, 2013.
  17. ^ a b c d Terry, Mark (November 29, 2018). "Can Moderna Live up to the Hype? mRNA Company Increases IPO Goal to $600 Million". BioSpace. Archived from the original on November 16, 2020. Retrieved May 19, 2020. The filings with the U.S. Securities and Exchange Commission (SEC) not only updated the proposed IPO but disclosed the size of the company's largest investors' stakes. Noubar B. Afeyan, company chairman, holds 19.5 percent, or 58,882,696 shares. Flagship Pioneering holds 18 percent of Moderna shares
  18. ^ a b Andrew Pollack (March 21, 2013). "AstraZeneca Makes a Bet on an Untested Technique". The New York Times. Archived from the original on November 16, 2020. Retrieved December 11, 2013.
  19. ^ Robert Weisman (March 21, 2013). "Moderna in line for $240m licensing deal". The Boston Globe. Archived from the original on November 16, 2020. Retrieved December 11, 2013.
  20. ^ "Moderna's gamble: what's behind biotech's biggest-ever IPO?". Pharmaceutical Technology. February 21, 2019. Archived from the original on November 16, 2020. Retrieved May 20, 2020.
  21. ^ "Our Pipeline". Modena. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  22. ^ Chris Reidy (January 13, 2014). "Alexion, Moderna announce agreement to develop messenger RNA therapeutics". The Boston Globe. Archived from the original on November 16, 2020. Retrieved March 18, 2020.
  23. ^ Dale, Alex (December 12, 2017). "Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017". Labiotech. Archived from the original on November 16, 2020. Retrieved May 20, 2020.
  24. ^ "Research not fit to print". Nature. 34 (115). February 5, 2016. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  25. ^ McGauley, Joe (September 23, 2018). "Why This Secretive Tech Start-Up Could Be The Next Theranos". Thrillist. Retrieved May 18, 2020.
  26. ^ Mukherjee, Sy (December 8, 2018). "Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future". Fortune. Archived from the original on November 16, 2020. Retrieved May 18, 2020.
  27. ^ Ramsey, Lydia (December 7, 2018). "Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion". Business Insider. Archived from the original on November 16, 2020. Retrieved May 18, 2020.
  28. ^ "Moderna stock price and market value". Yahoo Finance. December 4, 2020. Retrieved December 4, 2020.
  29. ^ Servick, Kelly (February 1, 2017). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines". Science. doi:10.1126/science.aal0686. Archived from the original on November 16, 2020. Retrieved May 17, 2018.
  30. ^ Cross, Ryan (April 3, 2020). "Will the coronavirus help mRNA and DNA vaccines prove their worth?". Chemical & Engineering News. 98 (14). Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  31. ^ Jackson, Lisa A.; Anderson, Evan J.; Rouphael, Nadine G.; Roberts, Paul C.; Makhene, Mamodikoe; Coler, Rhea N.; McCullough, Michele P.; Chappell, James D.; Denison, Mark R.; Stevens, Laura J.; Pruijssers, Andrea J. (July 14, 2020). "An mRNA Vaccine against SARS-CoV-2 — Preliminary Report". New England Journal of Medicine. 0 (20): 1920–1931. doi:10.1056/NEJMoa2022483. ISSN 0028-4793. PMC 7377258. PMID 32663912. At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection. All side effects were considered mild or moderate. A higher, 250-microgram dose led to more serious reactions and has been set aside. Although no side effects were severe — meaning that they required hospitalization — they were unpleasant, as was made clear when one volunteer in the study, Ian Haydon, went public with his experience taking the 250-microgram dose. {{cite journal}}: External link in |quote= (help)
  32. ^ a b Wink, Ben (May 18, 2020). "Here are the 5 multimillionaire scientists and executives getting the richest off Moderna's spike to record highs". Business Insider. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  33. ^ Egan, Matt; Isidore, Chris (May 22, 2020). "Moderna execs dumped nearly $30 million of stock after news of promising coronavirus vaccine". CNN. Archived from the original on November 16, 2020. Retrieved May 22, 2020.
  34. ^ Egan, Matt; Kuznia, Robert (June 1, 2020). "Moderna's coronavirus vaccine announcement set off a frenzy on Wall Street. Now some are calling for an investigation". CNN. Archived from the original on November 16, 2020. Retrieved June 1, 2020.
  35. ^ "Moderna's Board of Directors". Moderna. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  36. ^ "One Of Biotech's Biggest Investors Says The Industry Must Be 'Unreasonable'". www.wbur.org. Archived from the original on November 16, 2020. Retrieved July 15, 2020.
  37. ^ Corcoran, Kieran (May 16, 2020). "The ex-pharma exec leading Trump's COVID-19 vaccine program has $10 million in stock options for a company getting federal funding". Business Insider. Archived from the original on November 16, 2020. Retrieved May 18, 2020.
  38. ^ Steenhuysen, Julie; Kelland, Kate (January 24, 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Reuters. Archived from the original on January 25, 2020. Retrieved January 26, 2020.
  39. ^ Karen Carey (February 26, 2020). "Increasing number of biopharma drugs target COVID-19 as virus spreads". BioWorld. Archived from the original on February 27, 2020. Retrieved March 1, 2020.
  40. ^ Gwen Everett (February 27, 2020). "These 5 drug developers have jumped this week on hopes they can provide a coronavirus treatment". Markets Insider. Archived from the original on November 16, 2020. Retrieved March 1, 2020.
  41. ^ Pendleton, Devon; Maloney, Tom (May 18, 2020). "MIT Professor's Moderna Stake on the Brink of Topping $1 Billion". Bloomberg News. Retrieved May 18, 2020. CEO Bancel, other Moderna executives have been selling shares
  42. ^ "NIH clinical trial of investigational vaccine for COVID-19 begins". National Institutes of Health (NIH). March 16, 2020. Archived from the original on March 19, 2020. Retrieved March 18, 2020.
  43. ^ Kuznia, Robert; Polglase, Katie; Mezzofiore, Gianluca (May 1, 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on May 13, 2020. Retrieved May 2, 2020.
  44. ^ Alex Keown (May 7, 2020). "Moderna moves into Phase II testing of COVID-19 vaccine candidate". BioSpace. Archived from the original on November 16, 2020. Retrieved May 9, 2020.
  45. ^ Kyle Blankenship (May 1, 2020). "Moderna aims for a billion COVID-19 shots a year with Lonza manufacturing tie-up". FiercePharma. Archived from the original on November 16, 2020. Retrieved May 9, 2020.
  46. ^ "Swiss factory rushes to prepare for Moderna Covid-19 vaccine". SWI swissinfo.ch. Archived from the original on November 16, 2020. Retrieved October 7, 2020.
  47. ^ Clinical trial number NCT04405076 for "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older" at ClinicalTrials.gov
  48. ^ Staff, Reuters (June 25, 2020). "Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal". Reuters. Archived from the original on November 16, 2020. Retrieved November 6, 2020. {{cite news}}: |first= has generic name (help)
  49. ^ Lee, Jaimy. "Moderna signs on for another COVID-19 vaccine manufacturing deal". MarketWatch. Archived from the original on November 16, 2020. Retrieved July 9, 2020.
  50. ^ a b c Lisa A Jackson; mRNA-1273 Study Group (July 2020). "An mRNA Vaccine against SARS-CoV-2 — Preliminary Report". The New England Journal of Medicine. 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  51. ^ Lisa A Jackson; mRNA-1273 Study Group (July 2020). "Supplementary appendix for 'An mRNA Vaccine against SARS-CoV-2 — Preliminary Report'" (PDF). The New England Journal of Medicine. doi:10.1056/NEJMoa2022483. PMC 7377258. PMID 32663912. Archived (PDF) from the original on July 14, 2020. Retrieved July 15, 2020.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  52. ^ Yun Li (July 14, 2020). "Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus". CNBC. Archived from the original on November 16, 2020. Retrieved July 15, 2020.
  53. ^ a b Herper, Matthew; Garde, Damian (July 14, 2020). "First data for Moderna Covid-19 vaccine show it spurs an immune response". Boston Globe Media. statnews.com. Archived from the original on July 14, 2020. Retrieved July 15, 2020.
  54. ^ Hiltzik, Michael (May 19, 2020). "Column: Moderna's vaccine results boosted its share offering – and it's hardly a coincidence". The Los Angeles Times. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  55. ^ Branswell, Helen (May 19, 2020). "Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine". Stat. Archived from the original on November 16, 2020. Retrieved May 19, 2020.
  56. ^ Taylor, Marisa; Respaut, Robin (July 7, 2020). "Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials". Reuters. Archived from the original on November 16, 2020. Retrieved July 10, 2020.
  57. ^ Palca, Joe (July 27, 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on October 11, 2020. Retrieved July 27, 2020.
  58. ^ "Moderna, in bid for transparency, discloses detailed plan of coronavirus vaccine trial". BioPharma Dive. Archived from the original on November 16, 2020. Retrieved September 18, 2020.
  59. ^ Mascarenhas, Lauren (October 1, 2020). "Moderna chief says Covid-19 vaccine could be widely available by late March". CNN. Archived from the original on November 16, 2020. Retrieved October 2, 2020.
  60. ^ Correspondent, Elizabeth Cohen, CNN Senior Medical. "First large-scale US Covid-19 vaccine trial reaches target of 30,000 participants". CNN. Archived from the original on November 16, 2020. Retrieved October 23, 2020. {{cite web}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)
  61. ^ a b c d e Berkeley Lovelace, Jr.; Noah Higgins-Dunn (November 16, 2020). "Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar". CNBC. Retrieved November 17, 2020.
  62. ^ Zimmer, Carl (November 20, 2020). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. Retrieved November 21, 2020.
  63. ^ "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". Clinicaltrials.gov, US National Library of Medicine. October 28, 2020. Retrieved November 17, 2020.
  64. ^ "Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine". National Institutes of Health (NIH). November 15, 2020.
  65. ^ "Moderna vaccine trial contractors fail to enroll enough people of color, prompting slowdown". NBC News. Reuters. October 6, 2020. Retrieved November 17, 2020.
  66. ^ Dogan, Ellie (November 25, 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature. doi:10.1038/d41587-020-00022-y. PMID 33239758. S2CID 227176634. Retrieved November 30, 2020.
  67. ^ "Moderna Use Roche Antibody Test During Vaccine Trials". rapidmicrobiology.com. Retrieved 13 December, 2020.
  68. ^ Reuters (August 11, 2020). "Trump says U.S. inks agreement with Moderna for 100 mln doses of COVID-19 vaccine candidate". finance.yahoo.com. Archived from the original on November 16, 2020. Retrieved August 12, 2020. {{cite web}}: |last= has generic name (help)
  69. ^ "Moderna pitches virus vaccine at about $32-$37 per course". Financial Times. August 5, 2020. Archived from the original on November 16, 2020. Retrieved July 29, 2020.(subscription required)
  70. ^ "Donald Trump appears to admit Covid is 'running wild' in the US". The Guardian. November 22, 2020. ISSN 0261-3077. Retrieved November 22, 2020. Moderna told the Germany [sic] weekly Welt am Sonntag that it will charge governments between $25 and $37 per dose of its Covid vaccine candidate, depending on the amount ordered.
  71. ^ Guarascio, Francesco (November 24, 2020). "EU secures 160 million doses of Moderna's COVID-19 vaccine". Reuters. Retrieved November 25, 2020.
  72. ^ "Coronavirus: Commission approves contract with Moderna to ensure access to a potential vaccine". European Commission. November 25, 2020. Retrieved December 4, 2020.
  73. ^ "New agreements to secure additional vaccine candidates for COVID-19". Prime Minister's Office, Government of Canada. September 25, 2020. Retrieved December 4, 2020.
  74. ^ Parsons, Lucy (October 28, 2020). "UK's MHRA starts rolling review of Moderna's COVID-19 vaccine". PharmaTimes. Retrieved December 4, 2020.
  75. ^ Auth, Dorothy R.; Powell, Michael B. (September 14, 2020). "Patent Issues Highlight Risks of Moderna's COVID-19 Vaccine". New York Law Journal. Retrieved December 1, 2020.
  76. ^ Vardi, Nathan (June 29, 2020). "Moderna's Mysterious Coronavirus Vaccine Delivery System". Forbes. Retrieved December 1, 2020.
  77. ^ "Moderna loses key patent challenge". Nature Biotechnology. 38 (1009): 1009. 2020. doi:10.1038/s41587-020-0674-1. PMID 32887970. S2CID 221504018. Retrieved December 1, 2020.

External links

  • Official website
  • Business data for Moderna, Inc.:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Moderna&oldid=994115009"